Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-2121 Monotherapy and Combination in Advanced Solid Tumors
NCT06532565Phase 1Recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of GS-2121 in solid tumor (4 arms), sponsored by Gilead Sciences. Primary endpoints: Percentage of Participants with Adverse Events and Serious Adverse Events up to 118 weeks, Percentage of Participants with Laboratory Abnormalities up to 118 weeks and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
GS-2121
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06532565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532565.